Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05754788
Other study ID # 217/20
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date September 19, 2022
Est. completion date September 2023

Study information

Verified date May 2023
Source Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study aims at evaluating spatially resolved gene expression profiles of pancreatic and ampullary adenocarcinoma at favorable prognosis after surgical resection, in order to identify molecular features associated to a less aggressive biologic behavior that may benefit from upfront surgery.


Description:

Despite technical improvements, surgery for pancreatic adenocarcinoma is still burdened by poor survival outcomes of only 10% at 5 years, due to very high locoregional and distant recurrence rates. In order to improve such disappointing results, several studies are now focusing on the role of neoadjuvant treatment. Recent evidence shows that neoadjuvant treatment may achieve improved intention-to-treat survival outcome, increased rates of margin-negative resections and decreased incidence of lymph node metastases. However, all surgical series report that a limited subset of patients achieve long-term survival following radical surgical resection. After a systematic review of the available evidence on molecular profiling of pancreatic adenocarcinoma published until today the investigators have undertaken a retrospective study aimed at investigating the presence of possible genetic factors associated to a less aggressive clinical behavior. Clinical, biological and pathological features collected in a prospectively maintained database of radical surgery for pancreatic adenocarcinoma will be retrospectively reviewed together with an analysis of molecular features on surgical samples belonging to patients radically operated at the National Institute of Cancer of Milan. Such features may be used to identify those patients who may benefit from upfront surgery; in such group, vascular resections and reconstructions could be considered more liberally. The study will consist of 2 phases: 1. A preliminary exploratory phase (group A) based on approximately 20 surgical samples of patients with surgically resected pancreatic adenocarcinoma, not treated by neoadjuvant chemotherapy, in order to evaluate the intrinsic role of tumor biology and avoid the selection of molecular features associated to treatment response. This cohort will consist of 2 groups of 10 patients each with prognostically favorable (RFS≥60 months) and unfavorable tumors (RFS<12 months), respectively. Patients from the 2 groups will be matched for clinicopathological tumor-related features. Spatially resolved transcriptomic analysis will be performed by the GeoMx Digital Spatial Profiler (DSP) (NanoString Technologies, Seattle, WA, USA) on samples of the two groups and the resulting gene expression profiles will be compared, in order to identify different patterns of gene expression in prognostically different pancreatic adenocarcinomas. Such patterns will also be compared with the TCGA database. 2. A subsequent expanded phase, based on the results of the previous exploration, will take place in case a different gene expression profile is identified. The internal validation set (group B) consists in additional 20 surgical samples associated to favorable and unfavorable prognosis (10 patients each), respectively, belonging to the same institutional series and matched for clinicopathological tumor-related features. RNA-seq analysis will be carried out on these surgical samples, aiming at confirming the results of the exploratory analysis and refine the gene expression profile. In this subset, the enrolment of patients who underwent neoadjuvant treatment will be allowed. Due to the limited number, samples from patients affected by ampullary adenocarcinoma with favorable prognosis will be analyzed in one step and compared to matched cases with unfavorable prognosis (8 patients each, group C). Following the identification of gene expression profiles both for pancreatic and ampullary adenocarcinoma, an external validation set will be enrolled in order to perform RNA-seq analysis on additional 60-80 surgical samples from other institutions and validate the prognostic relevance of the identified pattern in predicting a less aggressive disease course.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 40
Est. completion date September 2023
Est. primary completion date May 2023
Accepts healthy volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: • Patients >18 years old undergoing surgical treatment with curative intent for pancreatic and ampullary adenocarcinoma between 1/1/2010 and 31/12/2017 with a regular follow-up and a RFS =36 months including: - Patients with locoregional lymph node metastases found at final pathology; - Patients with residual microscopic disease found at final pathology (R1 resections); - Presence of minimal extra-regional disease not detected pre-operatively (nodule of carcinosis, single liver metastasis, single extra-regional lymph node) and removed with the primary tumor within the same intervention. Exclusion Criteria: - Patients undergoing preoperative radiotherapy/chemotherapy for borderline resectable or initially unresectable tumors converted to surgical resection; - Patients with residual macroscopic disease after surgery (R1 resections); - Patients with metastatic disease found at laparotomy and contraindicating surgical resection, including unknown liver metastases, peritoneal carcinomatosis, distant lymph node disease; - Patients with unavailable follow-up or surgical samples for gene analysis.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Italy National Cancer Institute of Milan Milan

Sponsors (1)

Lead Sponsor Collaborator
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Country where clinical trial is conducted

Italy, 

References & Publications (3)

Pihlak R, Weaver JMJ, Valle JW, McNamara MG. Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. Cancers (Basel). 2018 Jan 12;10(1):17. doi: 10.3390/cancers10010017. — View Citation

Silvestris N, Brunetti O, Bittoni A, Cataldo I, Corsi D, Crippa S, D'Onofrio M, Fiore M, Giommoni E, Milella M, Pezzilli R, Vasile E, Reni M. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). Cancers (Basel). 2020 Jun 24;12(6):1681. doi: 10.3390/cancers12061681. — View Citation

Torres C, Grippo PJ. Pancreatic cancer subtypes: a roadmap for precision medicine. Ann Med. 2018 Jun;50(4):277-287. doi: 10.1080/07853890.2018.1453168. Epub 2018 Mar 22. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Favorable-prognosis gene expression pattern Identification of DSP gene aberrations associated to favorable prognosis (=60-month RFS) after radical surgery for pancreatic and ampullary adenocarcinoma, through comparison of prognostically favorable and unfavorable gene expression profiles found in different tumor and microenvironment compartments. 19/09/2022-29/09/2023
Secondary TCGA comparison Comparison of the gene expression profile found at DSP with the TCGA database in order to confirm the clinical relevance of the identified gene expression pattern associated to prognostically favorable tumors 19/09/2022-29/09/2023
Secondary Clinical, biological and pathological factors Identification of clinical, biological and pathological prognostic factors associated to favorable prognosis (=60-month RFS) after radical surgery for pancreatic adenocarcinoma 19/09/2022-29/09/2023
Secondary External validation of gene expression profile External validation of the identified gene expression profile through gene expression analysis of surgical samples from patients undergoing radical surgery for pancreatic adenocarcinoma in a different institution 19/09/2022-29/09/2023
See also
  Status Clinical Trial Phase
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT04940286 - Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer Phase 2
Recruiting NCT05066802 - A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma Phase 2
Recruiting NCT04858334 - APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation Phase 2
Completed NCT00600002 - Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma Phase 1
Recruiting NCT03251365 - Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer Phase 2/Phase 3
Not yet recruiting NCT06423326 - Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer Phase 2
Recruiting NCT04340141 - Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer Phase 3
Recruiting NCT05275075 - Identify microRNAs in Cachexia in Pancreatic Carcinoma
Not yet recruiting NCT06168552 - Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer Phase 1/Phase 2
Completed NCT03273374 - Intraoperative Radiation Therapy for Resectable Pancreatic Cancer N/A
Not yet recruiting NCT04915417 - Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma N/A